Trough anti-Xa activity after intermediate dose nadroparin for thrombosis prophylaxis in critically ill patients with COVID-19 and acute kidney injury

Our objective was to assess the incidence of drug bioaccumulation in critically ill COVID-19 patients with AKI receiving intermediate dose nadroparin for thrombosis prophylaxis. We conducted a Prospective cohort study of critically ill COVID-19 patients. In patients on intermediate dose nadroparin (...

Descripción completa

Detalles Bibliográficos
Autores principales: Eck, R. J., van de Leur, J. J. C. M., Wiersema, R., Cox, E. G. M., Bult, W., Spanjersberg, A. J., van der Horst, I. C. C., Lukens, M. V., Gans, R. O. B., Meijer, K., Keus, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579123/
https://www.ncbi.nlm.nih.gov/pubmed/36257974
http://dx.doi.org/10.1038/s41598-022-21560-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579123/
https://www.ncbi.nlm.nih.gov/pubmed/36257974
http://dx.doi.org/10.1038/s41598-022-21560-2

Ejemplares similares